Knight Therapeutics | GUD - Selling And Administration Expenses



Knight Therapeutics reported CAD25.48M in Selling and Administration Expenses for its fiscal quarter ending in September of 2024.


Selling And Administration Expenses Change Date
Acasti Pharma USD 2.14M 2.14M Jun/2025
Alaunos Therapeutics USD 845K 162K Dec/2024
Aurora Cannabis CAD 45.63M 7.45M Jun/2025
Avita Medical AUD 21.23M 2.57M Dec/2024
Canopy Growth CAD 40.12M 504K Jun/2025
Cronos Group USD 15.88M 79K Jun/2025
Dianthus Therapeutics USD 8.87M 2.04M Jun/2025
Ionis Pharmaceuticals USD 90.6M 14.6M Jun/2025
IQVIA Holdings USD 509M 1000K Jun/2025
Knight Therapeutics CAD 25.48M 119K Sep/2024
Moderna USD 230M 18M Jun/2025
Organigram Holdings CAD 25.49M 8.3M Jun/2025
Organon & Co USD 453M 33M Jun/2025
Revvity USD 248.53M 1.19M Jun/2025
Tectonic Therapeutic USD 5.15M 315K Jun/2025
Tilray USD 72.38M 4.99M Nov/2024
Viatris USD 928.7M 111.2M Jun/2025
Xeris Pharmaceuticals USD 44.39M 35.89M Jun/2025